SCHEMBL3854568

SCHEMBL3854568

CCOC(=O)c1c(O)c(C(C)(C)C)nn(Cc2ccc(C(C)(C)C)cc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
EGLN3 Q9H6Z9 1/20 0.46
MAPK1 P28482 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 3/20 0.41
NPC1 O15118 1/20 0.41
RECQL P46063 1/20 0.40
ADORA1 P30542 1/20 0.40
TP53 P04637 1/20 0.40
FEN1 P39748 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849282 0.88 MAPK1 (0.48) ALDH1A1EGLN3MAPK1KDM4ELMNA
SCHEMBL3845820 0.87 EGLN3 (0.61) ALDH1A1KMT2AMEN1EGLN3MAPK1
SCHEMBL3856858 0.86 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1EGLN3MAPK1
SCHEMBL3851331 0.84 EGLN3 (0.58) ALDH1A1KMT2AMEN1EGLN3MAPK1
SCHEMBL3845767 0.83 EGLN3 (0.68) ALDH1A1KMT2AMEN1EGLN3MAPK1
SCHEMBL3846045 0.82 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1EGLN3MAPK1
SCHEMBL3856401 0.82 ALDH1A1 (0.53) ALDH1A1MAPK1CYP2C9CYP2C19KDM4E
SCHEMBL3852981 0.81 KDM4E (0.48) ALDH1A1KMT2AMEN1MAPK1KDM4E
SCHEMBL3851359 0.80 MAPK1 (0.54) ALDH1A1KMT2AMEN1MAPK1KDM4E
SCHEMBL3857672 0.80 KDM4E (0.47) ALDH1A1MAPK1KDM4ELMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885KMT2A 495/4885MEN1 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.